Acetyl-CoA Carboxylase Inhibition as a Therapeutic Tool in the Battle Against NASH: Hitting More Than Just One Mechanism?
Cell Mol Gastroenterol Hepatol
.
2020;10(4):859-861.
doi: 10.1016/j.jcmgh.2020.07.002.
Epub 2020 Jul 27.
Authors
Joeri Lambrecht
1
,
Frank Tacke
2
Affiliations
1
Department of Hepatology and Gastroenterology, Charité University Medicine Berlin, Berlin, Germany.
2
Department of Hepatology and Gastroenterology, Charité University Medicine Berlin, Berlin, Germany. Electronic address: frank.tacke@charite.de.
PMID:
32730829
PMCID:
PMC7573675
DOI:
10.1016/j.jcmgh.2020.07.002
No abstract available
Publication types
Editorial
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Acetyl-CoA Carboxylase*
Humans
Non-alcoholic Fatty Liver Disease* / drug therapy
Substances
Acetyl-CoA Carboxylase